Disclaimer

The following content discusses the Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by the FDA-cleared RenovoCath. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

RenovoRx is evaluating the use of TAMP with gemcitabine as a combination product (known as intra-arterial gemcitabine) for the treatment of locally advanced pancreatic cancer (LAPC), including in the ongoing Phase III TIGeR-PaC trial, under a U.S. Investigational New Drug Application. Ongoing clinical studies continue to evaluate safety and clinical outcomes in patients with LAPC. For RenovoCath’s Indications for Use and safety information, please visit IFU.

Learn more about how hospitals are using the TAMP™ therapy platform with the RenovoCath® device in oncology management, and participant experiences in the Phase III TIGeR-PaC clinical trial.*

Doctors Testing 'Groundbreaking' Treatment for Pancreatic Cancer

john-wilbur-and-wife.jpg

CHARLOTTE, N.C. — A new treatment for pancreatic cancer is being tested out in clinical trials in several states, and one North Carolina doctor called it “groundbreaking.”

The trials are being conducted in multiple cities across the country, including in North Carolina, California, New York, Florida and others along the East and West coasts.

View the entire article and watch the video on Spectrum News 1

RenovoRx is participating in clinical trials and the FDA has not determined the safety and or efficacy of its clinical drug development program.
View All Clinical News